Literature DB >> 17537847

Antibody binding in proximity to the receptor/glycoprotein complex leads to a basal level of virus neutralization.

Xinzhen Yang1, Inna Lipchina, Michelle Lifton, Liping Wang, Joseph Sodroski.   

Abstract

Hypothetically, antibodies may neutralize enveloped viruses by diverse mechanisms, such as disruption of receptor binding, interference with conformational changes required for virus entry, steric hindrance, or virus aggregation. Here, we demonstrate that retroviral infection mediated by the avian sarcoma-leukosis virus (ASLV-A) envelope glycoproteins can be neutralized by an antibody directed against a functionally unimportant component of a chimeric receptor protein. Thus, the binding of an antibody in proximity to the retroviral envelope glycoprotein-receptor complex, without binding to the entry machinery itself, results in neutralization. This finding provides additional support for the hypothesis that steric hindrance is sufficient for antibody-mediated neutralization of retroviruses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537847      PMCID: PMC1951382          DOI: 10.1128/JVI.00394-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

Review 1.  Antibody and virus: binding and neutralization.

Authors:  D R Burton; R A Williamson; P W Parren
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

2.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.

Authors:  P E Finke; B Oates; S G Mills; M MacCoss; L Malkowitz; M S Springer; S L Gould; J A DeMartino; A Carella; G Carver; K Holmes; R Danzeisen; D Hazuda; J Kessler; J Lineberger; M Miller; W A Schleif; E A Emini
Journal:  Bioorg Med Chem Lett       Date:  2001-09-17       Impact factor: 2.823

Review 3.  Occupancy and mechanism in antibody-mediated neutralization of animal viruses.

Authors:  P J Klasse; Q J Sattentau
Journal:  J Gen Virol       Date:  2002-09       Impact factor: 3.891

4.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

Authors:  J J Hale; R J Budhu; E B Holson; P E Finke; B Oates; S G Mills; M MacCoss; S L Gould; J A DeMartino; M S Springer; S Siciliano; L Malkowitz; W A Schleif; D Hazuda; M Miller; J Kessler; R Danzeisen; K Holmes; J Lineberger; A Carella; G Carver; E Emini
Journal:  Bioorg Med Chem Lett       Date:  2001-10-22       Impact factor: 2.823

5.  Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Svetla Kurteva; Sandra Lee; Joseph Sodroski
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Genetic mapping of the cloned subgroup A avian sarcoma and leukosis virus receptor gene to the TVA locus.

Authors:  P Bates; L Rong; H E Varmus; J A Young; L B Crittenden
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.

Authors:  Xinping Ren; Joseph Sodroski; Xinzhen Yang
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Svetla Kurteva; Xinping Ren; Sandra Lee; Joseph Sodroski
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  The avian retrovirus avian sarcoma/leukosis virus subtype A reaches the lipid mixing stage of fusion at neutral pH.

Authors:  Laurie J Earp; Sue E Delos; Robert C Netter; Paul Bates; Judith M White
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 10.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

View more
  4 in total

1.  Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.

Authors:  Pengcheng Wang; Xinzhen Yang
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

2.  Binding of transmembrane mucins to galectin-3 limits herpesvirus 1 infection of human corneal keratinocytes.

Authors:  A M Woodward; J Mauris; P Argüeso
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

3.  The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions.

Authors:  Ralph Pantophlet; Meng Wang; Rowena O Aguilar-Sino; Dennis R Burton
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

4.  Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.

Authors:  Barry Rockx; Davide Corti; Eric Donaldson; Timothy Sheahan; Konrad Stadler; Antonio Lanzavecchia; Ralph Baric
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.